- Affirmative Recovery
- Alternative Dispute Resolution
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
November 20, 2020Phil Sieff Selected as a Fellow of the Litigation Counsel of America
-
November 20, 2020Robins Kaplan Named Breastfeeding-Friendly Workplace
-
November 16, 2020David Martinez Elected to Robins Kaplan Executive Board
-
December 1-10, 20207th Annual IP Dealmakers Forum
-
December 11, 2020LGBTQ Legal Services: Transgender Name Change Clinic
-
December 17, 2020Valuation: The “Eye of the Beholder” Causes Disputes
-
November 2020Explaining the Almost Unexplainable
-
November 12, 2020If Your Company Received a Paycheck Protection Program Loan - The SBA Wants to Know How Necessary Was Your Loan
-
November 9, 2020Hatch-Waxman Venue Is Further Narrowed
-
November 25, 2020Financial Daily Dose 11.25.2020 | Top Story: Dow Jones Hits 30,000 Mark
-
November 24, 2020Financial Daily Dose 11.24.2020 | Top Story: Biden Taps Former Fed Chair Yellen as Treasury Pick
-
November 23, 2020Financial Daily Dose 11.23.2020 | Top Story: Pandemic and Global Economy Dominate Virtual G-20 Meeting
Zofran
You must read the following notice before sending an e-mail message to Robins Kaplan LLP.
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
For further inquiries about Zofran, feel free to call us toll free at 1.800.553.9910, or send an e-mail by using the form.
Consumer Alert: Popular Anti-Nausea Drug Zofran Linked to Birth Defects
Zofran is an anti-nausea drug not FDA-approved for use during pregnancy, but often prescribed "off label" for morning sickness. It is associated with an increased risk of cleft palate and congenital heart defects.1
1 M. Anderka et al. Medications Used to Treat Nausea and Vomiting of Pregnancy and Risk of Selected Birth Defects. Birth Defects Res A Clin Mol Teratol. (Jan. 2012); JT Anderson et al. Ondansetron use in Early Pregnancy and the Risk of Congenital Malformations – A Register Based Nationwide Cohort Study. Pharmacoepidemiology and Drug Safety. (Oct. 2013)
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.